This study demonstrated that PRXT treatment could prevent bleomycin-induced pulmonary fibrosis in vivo and in vitro by regulating GRK2/Smad3 signaling pathway (Figure 7I). This evidence concerns the gene SMAD3 and pulmonary fibrosis.